Altium Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Altium Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-66,000	Closed	-$2.25M	–	129
2022 Q1	$2.25M	Sell	66,000 -60,000	-48%	-$1.92M	0.75%	47
2021 Q4	$4.87M	Sell	126,000 -59,000	-32%	-$2.57M	1.34%	26
2021 Q3	$9.99M	Buy	185,000 +91,884	+99%	+$4.31M	2.62%	3
2021 Q2	$3.11M	Buy	93,116 +48,103	+107%	+$1.32M	0.72%	59
2021 Q1	$927K	Sell	45,013 -194,507	-81%	-$4.47M	0.26%	112
2020 Q4	$4.2M	Buy	+239,520	New	+$4.31M	1.57%	19

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Altium Capital Management's CLDX Position: Q2 2022 in Review

Altium Capital Management sold out of Celldex Therapeutics (CLDX) in Q2 2022, closing a stake of 66,000 shares — an estimated $2.25M sold.

Altium Capital Management first reported a position in CLDX in Q4 2020 and held it in 6 quarters. The position peaked at $9.99M in Q3 2021. 157 funds tracked by Wall St. Rank hold CLDX as of Q2 2022.

Altium Capital Management reported no remaining Celldex Therapeutics position as of Q2 2022 after selling out during the quarter.
Altium Capital Management sold 66,000 Celldex Therapeutics shares in Q2 2022, an estimated $2.25M.
Altium Capital Management first reported a position in Celldex Therapeutics in Q4 2020 and held it in 6 quarters.
Altium Capital Management's Celldex Therapeutics position peaked at $9.99M in Q3 2021.
157 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2022.

Based on Altium Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.